A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia

A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia

The therapeutic approach to chronic myeloid leukaemia (CML) has changed in recent years. As a result, a high percentage of current patients in the chronic phase of the disease almost have an average life expectancy. Treatment also aims to achieve a stable deep molecular response (DMR) that might all...

Full description

Bibliographic Details
Main Authors: Alicia Martín Roldán, María Del Mar Sánchez Suárez, Carolina Alarcón-Payer, Alberto Jiménez Morales, José Manuel Puerta Puerta
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Pharmaceutics
Subjects:
chronic myeloid leukaemia
tyrosine kinase inhibitors
treatment-free remission
molecular recurrence-free survival
low dose
adverse event
Online Access:https://www.mdpi.com/1999-4923/15/5/1363

Similar Items

Similar Items